Pure Global
NCT04512534

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

A Phase II Study of Anti-Programmed Death-1(PD-1) Antibody Sintilimab Plus Histone Deacetylase(HDAC) Inhibitor Chidamide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma
Fudan University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
PD-1 antibody+ HDAC inhibitor
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fudan University
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Nov 13, 2020
End date
Sep 01, 2025
Enrollment
51 participants
Primary outcome

Progression Free Survival (PFS)

Summary

This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of
 Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with
 relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04512534
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04512534 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 51 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.